Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)

NCT02682693 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT02682693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02682693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 2
Overall status
Completed
Start date
February 13, 2017
Completion date
December 31, 2020
Enrollment
780 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female nos, her2 positive breast cancer, inflammatory breast cancer, invasive ductal breast cancer, mucinous breast cancer stage ii, tubular breast cancer stage ii, tubular breast cancer stage iii